Formulation and evaluation of dosage form of fast dissolving oral film of Rofecoxib
Department of Pharmaceutical Analysis, Mother Teresa Pharmacy College, Sathupally, Telangana – 507303, India.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(01), 371–381.
Article DOI: 10.30574/wjbphs.2024.19.1.0449
Publication history:
Received on 12 June 2024; revised on 20 July 2024; accepted on 22 July 2024
Abstract:
Rofecoxib is utilized for the treatment of osteoarthritis, rheumatoid joint inflammation, intense torment in grown-ups, and essential dysmenorrhea, just as intense therapy of headache assaults with or without emanations. Rofecoxib is strong. This compound has a place with the stilbenes. These are natural mixes containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are acquired from the normal phenylpropene (C6-C3) skeleton building block. The presentation of at least one hydroxyl gathering to a phenyl ring leads to stilbenoids. Rofecoxib has a half-existence of 17 hours and its mean oral bioavailability at restoratively suggested dosages of 125,25,and 50 mg is roughly 93%. The proteins that rofecoxib target incorporate elastin and prostaglandin G/H synthase Cytochrome P4501A2, Cytochrome P4503A4, Cytochrome P4502C9, Cytochrome P4502C8, and Prostaglandin G/H synthase1 are known to processor of Rofecoxib. Rofecoxib oral thin films were prepared from the evaluation studies RCX2 with 98.14% drug release is considered as the optimized formulation.
Keywords:
Rofecoxib; Oral thin films; Fast Dissolving
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0